Kuano combines quantum physics, AI and medicinal chemistry in an approach to transforming the discovery of therapeutics focused on enzyme inhibition. Enzymes represent the largest class of drug targets, with over $40 billion of pharmaceutical sales attributable to small molecule inhibitors of enzymes. The market is seeing considerable demand for enzyme inhibitors, which can provide …

Founded through a collaboration between argenx and the University of Torino, Italy – Agomab is translating deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, it is …

ELEM Biotech is developing a Virtual Human technology that it hopes to become the standard for medical testing and in-silico clinical trials. More specifically, the company is creating cutting-edge supercomputer-based patient modeling and simulation solutions, deployed in the cloud, that help MedTech and Pharma companies, and CROs optimize their products and offer new evidence to …

CancerAppy has developed a platform based on Big Data and AI, specialized in the field of cancer research, developed by and for scientists and drug developers that fills the gap between basic data tools and pharma intelligence tools. Said platform is meant to efficiently and effectively de-risk the process of cancer drug discovery and development …